

Supplementary Materials and Methods

Immunofluorescence studies

Fluorescence microscopy studies were performed as described previously¹. Cells were fixed with methanol (100%; -20° C, 2 minutes) prior incubation with blocking solution and the addition of the primary antibodies (1:50). All primary antibodies were diluted in 1% BSA (1 hour; room temperature). After primary antibody incubation, cells were washed three times with PBS, and afterwards samples were incubated with Alexa Fluor 488- or Alexa Fluor 555- conjugated anti-mouse, for 1 hour at room temperature (1:1000) and mounted in Vectashield mounting medium. Cells were visualized in a Nikon eclipse 80i microscope with the appropriate filters. Representative images were taken with a Nikon DS-Ri1 digital camera and edited in Adobe Photoshop. Primary antibodies used: E-Cadherin, #610182 from BD Transduction Laboratories (Erembodegem, Belgium); Vimentin, #V6630 from Sigma-Aldrich (St. Louis, MO, USA); ZO-1, #61-7300 from Invitrogen (Waltham, MA, USA); Cytokeratin 18, #61028 from Progen (Heidelberg, Germany). Phalloidin (#P1951K) and Dapi (4',6-Diamidino-2-Phenylindole, Dihydrochloride, #32670) were from Sigma-Aldrich (St. Louis, MO, USA).

Analysis of gene expression

Real-time quantitative PCR reactions were performed using the following human specific primers designed by Integrated DNA Technologies (IDT):

L32	Forward: 5'-AACGTCAAGGAGCTGGAAG-3' Reverse: 5'-GGGTTGGTGACTCTGATGG-3'
CDH1	Forward: 5'-CCCAATACATCTCCCTTCACAG-3' Reverse 5'-CCACCTCTAAGGCCATCTTG-3'
KRT18	Forward: 5'-CAGAGACTGGAGCCATTACTC-3' Reverse: 5'-GCCAGCTCTGTCTCATACTTG-3'
VIM	Forward: 5'- GGAAGCCTAACTACAGCGAG -3'

	Reverse: 5'- CAGAGTCCCAGATGAGCATTG -3'
SNAI1	Forward: 5'-GCTGCAGGACTCTAATCCAGAGTT-3'
	Reverse: 5'-GACAGAGTCCCAGATGAGCATTG-3'
SNAI2	Forward: 5'- ACACATTAGAACTCACACGGG -3'
	Reverse: 5'- TGGAGAACGGTTGGAGCAG -3'
ZEB2	Forward: 5'-AGGCATATGGTGACGCACAA-3'
	Reverse: 5'-CTTGAACCTGCGGTTACCTGC-3'
TWIST1	Forward: 5'-CTCAGCTACGCCCTCTCG-3'
	Reverse: 5'-ACTGTCCATTTCCTCCTCTG-3'
ACACA	Forward: 5'- CTGGAGGTGTATGTTCGAAGG -3'
	Reverse: 5'- TCTGTTAGCGTAGGGATGTTC -3'
ACACB	Forward: 5'- CCCCAGACAAGTATCCCAAAG -3'
	Reverse: 5'- GGGTACTCCTGGGTCTTAAAC-3'

Targeted know-down assays

Hep3B and SNU449 cell line was transfected with a combination of 4 shRNA plasmids for TGF β RI as well as a control unspecific shRNA. After 24 hours, media was changed to complete media, and selection of transfected cells was done with puromycin (for 50 days prior to experiments).

shRNA plasmids were selected from Mission SH (Sigma-Aldrich, St Louis, USA) with following sequences:

shT β RI:

```
#1 -CCGGCTCATGTTGATGGTCTATATCCTCGAGGATATAGACCATCAACATGAGTTTTG-
#2 -CCGGGAAGTTGCTGTTAAGATATTCCCTCGAGGAATATCTAACAGCAACTTCTTTTG-
#3 -CCGGGATCATGATTACTGTCGATAACTCGAGTTATCGACAGTAATCATGATCTTTTG-
#4 -CCGGGCTGGCTTAACTTAGGTAACTCGAGTTACCTAAAGTTAACGACCAGCTTTTG-
```

Migration assay

Real-time assay of cell motility was examined through the xCELLigence System (ACEA Biosciences, San Diego, USA) as previously described¹. 4x10⁴cells/well were seeded onto the top chamber of a CIM plate®, which was coated with a collagen IV solution (Sigma-Aldrich) and placed onto the Real-Time Cell Analyzer (RTCA) station (ACEA Biosciences, San Diego, USA). Continuous values were represented as Cell Index (CI), a dimensionless parameter, which reflects a relative change in measured electrical impedance, and quantified as a slope (h⁻¹) of the first 8 hours of cell migration.

Seahorse analysis

For the XF Cell Mito Stress analysis, ATP synthase inhibitor oligomycin (1 μM) was injected to block proton movement and therefore oxidative phosphorylation. Consequently, carbonyl cyanide-4-(trifluoromethoxy) phenylhydrazone (FCCP, 0.5 μM) re-establishes proton movement by disrupting the mitochondrial membrane potential to stimulate maximal OCR and electron transport. At last, a combination of rotenone (1 μM) and antimycin (1 μM) was added to block complex I and III respectively and therefore completely block the mitochondrial respiration. The values obtained after injection of rotenone and antimycin were considered as non-mitochondrial respiration. The basal OCR was calculated as the last OCR measurement prior the addition of oligomycin minus the last OCR measurement after the addition of antimycin and rotenone. The ATP-linked OCR was calculated as the last OCR measurement prior oligomycin injection minus the last OCR measurement after the addition of oligomycin. The maximal OCR was calculated as the last OCR measurement after FCCP injection minus the last OCR measurement after the addition of antimycin and rotenone.

For the XF Glycolysis stress kit, glucose (10 mM) was injected, followed by oligomycin (1 μM), which as an ATP inhibitor permits the readout of the maximal ECAR. Finally, 2-DG (50 mM) was added to completely block glycolysis. The level of glycolysis is calculated as the last ECAR measurement after glucose injection minus the last ECAR measurement after the addition of 2-DG. The glycolytic capacity is calculated as the last ECAR measurement after oligomycin

injection minus the last ECAR measurement after 2-DG injection. The glycolytic reserve is calculated as the glycolytic capacity minus glycolysis.

Lactate production assay

The concentration of L-lactate was determined using an enzymatic reaction based on the oxidation of L-lactate to pyruvate by lactate dehydrogenase (5 mg of the enzyme (Roche, Basel, Switzerland)/ml, 550 U/mg) in the presence of NAD⁺ (Sigma Aldrich) as previously described². In this assay, the amount of NADH produced in the reaction is proportional to the amount of L-lactate in the samples. With this enzymatic system, D-lactate is not detected. All experiments were carried out at least 3 times in triplicates. The collected culture medium were diluted 1:20 with reaction mix [0.3 M hydrazine sulfate (Sigma Aldrich) and 0.87 M glycine (Sigma Aldrich)], pH 9.5; 2.5 M NAD⁺ (Sigma Aldrich) and 0.19 M EDTA (Sigma Aldrich). Lactate dehydrogenase was added at a final concentration of 6.9 U/ml. The NADH concentration was determined as absorbance at 340 nm on a plate reader after 0 and 20 minutes after the start of the reaction. After the subtraction of absorbance at time 0, the absorbance at 20 minutes was normalization to L-lactate standards [(a serial dilution of sodium L-lactate (Sigma Aldrich)], obtained L-lactate concentrations were normalized to respective cell numbers.

Glucose consumption assay


The concentration of glucose was determined using a glucose oxidase and peroxidase method, PGO Enzymes (Sigma Aldrich) according to manufacturer's instructions. Briefly, to prepare the PGO enzyme reaction solution, 100 ml PGO Enzymes solution (1 PGO capsule in 100 ml of distilled water) was mixed with 1.6 ml of the o-Dianisidine solution [50 mg of o-Dianisidine hydrochloride (Sigma Aldrich) in 20 ml of distilled water]. Medium samples were diluted (1/20 in distilled water) and 15 µl of sample was added to 200 µl of prepared reaction mix. After 30 minutes incubation at 37°C, absorbance was read on a plate reader at 450 nm. Different concentrations of glucose solution (Sigma Aldrich) served as the standards. The glucose

consumption was calculated as the glucose concentration of medium control (no cells) minus the glucose concentration of individual samples. All experiments were carried out at least 3 times in triplicates.

References


- 1 Bertran, E. *et al.* Overactivation of the TGF- β pathway confers a mesenchymal-like phenotype and CXCR4-dependent migratory properties to liver tumor cells. *Hepatology* **58**(6), 2032-2044 (2013).
- 2 Álvarez, Z., Hyrošová, P., Perales, J. & Alcántara, S. Neuronal Progenitor Maintenance Requires Lactate Metabolism and PEPCK-M-Directed Cataplerosis. *Cereb Cortex* **26**(3), 1046-1058 (2016).

A



B

E-CADHERIN / DAPI



C




Figure S1 - Treatment of Hep3B cells with TGF- β induces Epithelial-Mesenchymal Transition (EMT), an effect that is abrogated when the TGF- β receptor I (T β RI) is silenced.

Hep3B cells, stably transfected with shcontrol (sh-) or specific T β RI shRNA (A.) were cultured in the absence (Control) or in the presence of TGF- β (2 ng/ml) for 24 and/or 48 h, as indicated in each graph: (B.): Immunofluorescence analysis of E-cadherin (green), DAPI (nuclei) in blue. Scale bar represents 50 μ m. (C.): mRNA expression levels of EMT-related genes (E-CADHERIN: *CDH1*; VIMENTIN: *VIM*) and EMT-inducing transcription factors (*SNAI1*, *SNAI2*, *TWIST1* and *ZEB2*) were detected by qRT-PCR and normalized to housekeeping gene L32. Mean \pm SD (n=3). *p<0.05, **p<0.01, ***p<0.001, compared as indicated in the graphs.






A**B****C**

Figure S2 - Generation of T_βT-Hep3B (Chronic TGF- β -treated Hep3B) cells.

Hep3B cells were treated with TGF- β (2 ng/ml) for two weeks. Media was replaced every two days. (A.) Immunofluorescence analysis of E-cadherin (green), Cytokeratin 18 (green) and vimentin (orange). DAPI (blue). Scale bar represents 50 μm. (B.) mRNA expression levels of EMT-related genes (*CDH1*, *VIM*, *KRT18*) and EMT-inducing transcription factors (*SNAI1*, *SNAI2*, *ZEB2*) analysed by qRT-PCR and normalized to housekeeping gene L32. Mean±SD (n=3). *p<0.05, **p<0.01 as compared to Hep3B. (C.) Analysis of cell migration by real-time assay (xCELLigence system) between Hep3B and T_βT-Hep3B. Left: A representative experiment is shown. Right: Quantification as a slope (hour⁻¹) of the first 8 hours of cell migration normalized to Hep3B. Mean±SD (n=3). ***p<0.001 as compared to Hep3B.

A

Statistical Comparisons Welch's Two-Sample t-Test	
Significantly Altered Biochemicals	T β T-Hep3B Hep3B
Total biochemicals $p \leq 0.05$	151
Biochemicals (↑↓)	63 88
Total biochemicals $0.05 < p < 0.10$	78
Biochemicals (↑↓)	50 28

B T β T-Hep3B/Hep3B**C****Figure S3 - Metabolomic analysis of T β T-Hep3B/Hep3B cells.**

(A.) A total of 561 metabolites were detected. Welch's two-sample *t*-test was used to identify biochemicals that differed significantly ($p < 0.05$) and with approaching significance ($0.05 < p < 0.10$) between experimental groups ($n=5$ for each group). **(B.)** Pathway set enrichment analysis was performed using MetaboLync™ platform and followed formula: # of significant metabolites in pathway (k) / total # of detected metabolites in pathway (m)) / [total # of significant metabolites (n) / total # of detected metabolites(N)] (k/m)/(n/N). **(C.)** Hierarchical clustering was performed using Euclidean distance method by Metabolon Inc.




A**B****C**

Figure S4 – Effect of silencing the TGF- β receptor I (T β RI) in the mesenchymal HCC cell line SNU449.

SNU449 cells, control (sh-) or stably silenced with specific T β RI shRNA (A.) mRNA expression levels of *TGFBR1* and the EMT-inducing transcription factors (*SNAI1*, *TWIST1* and *ZEB1*) were detected by qRT-PCR and normalized to housekeeping gene L32. (B.): Immunofluorescence analysis of Vimentin and ZO1 (green) and staining analysis of F-Actin with phalloidin (red), DAPI (nuclei) in blue. Scale bar represents 50 μ m. (C.) Analysis of cell migration by real-time assay (xCELLigence system) between Hep3B and T β T-Hep3B. Left: A representative experiment is shown. Right: Quantification as a slope (hour-1) of the first 8 hours of cell migration. In A. and C.: Mean \pm SD (n=3). *p<0.05, **p<0.01, ***p<0.001, compared as the graph indicates.

Table S1.List of detected metabolites in T β T-Hep3B compared to Hep3B

Sub Pathway	Biochemical Name	T β T-Hep3B Hep3B	p value
Short Chain Fatty Acid	valerate	1.40	0.2504
Medium Chain Fatty Acid	caproate (6:0)	1.52	0.0839
	caprylate (8:0)	1.43	0.1645
	laurate (12:0)	1.10	0.9904
	5-dodecanoate (12:1n7)	1.15	0.6963
Long Chain Fatty Acid	myristate (14:0)	1.32	0.1339
	myristoleate (14:1n5)	1.24	0.5979
	pentadecanoate (15:0)	1.32	0.0179
	palmitate (16:0)	1.15	0.2517
	palmitoleate (16:1n7)	1.22	0.3616
	margarate (17:0)	1.76	0.0061
	10-heptadecenoate (17:1n7)	1.51	0.0031
	stearate (18:0)	1.43	0.0066
	nonadecanoate (19:0)	1.26	0.1043
	10-nonadecenoate (19:1n9)	3.05	0.0003
	arachidate (20:0)	1.23	0.1794
	eicosenoate (20:1)	2.30	0.0001
	tricosenoate (23:1)	2.68	0.0039
	behenate (22:0)	1.96	0.1175
	erucate (22:1n9)	1.76	0.0007
Polyunsaturated Fatty Acid (n3 and n6)	oleate/vaccenate (18:1)	1.72	0.0005
	stearidonate (18:4n3)	1.51	0.0908
	eicosapentaenoate (EPA; 20:5n3)	0.80	0.2494
	docosapentaenoate (n3 DPA; 22:5n3)	2.78	0.0081
	docosahexaenoate (DHA; 22:6n3)	0.96	0.7408
	docosatrienoate (22:3n3)	2.32	0.0079
	linoleate (18:2n6)	1.52	0.0027
	linolenate [alpha or gamma; (18:3n3 or 6)]	1.30	0.1831
	dihomo-linolenate (20:3n3 or n6)	1.92	0.0429
	arachidonate (20:4n6)	0.95	0.8391
	adrenate (22:4n6)	6.13	0.1290
	docosapentaenoate (n6 DPA; 22:5n6)	2.18	0.0284
	docosadienoate (22:2n6)	2.57	0.0000
	dihomo-linoleate (20:2n6)	3.09	0.0007
Fatty Acid, Branched	mead acid (20:3n9)	1.91	0.0053
	13-methylmyristate	1.73	0.0005
	15-methylpalmitate	1.67	0.0002
Fatty Acid, Dicarboxylate	17-methylstearate	1.94	0.0071
	2-hydroxyglutarate	0.31	0.0051
	2-hydroxyadipate	0.56	0.1234
	maleate	0.80	0.2015
Fatty Acid Metabolism	pimelate (heptanedioate)	2.30	0.0410
	acetyl CoA	1.00	---
Fatty Acid Metabolism (also)	butyrylcarnitine	0.13	0.0729
	butyrylglycine	1.20	0.3737

BCAA Metabolism)	propionylcarnitine	0.88	0.3739
	methylmalonate (MMA)	8.03	0.0221
Fatty Acid Metabolism(Acyl Glycine)	N-palmitoylglycine	1.00	---
Fatty Acid Metabolism(Acyl Carnitine)	acetylcarnitine	0.37	0.0133
	3-hydroxybutyrylcarnitine (1)	0.29	0.0303
	3-hydroxybutyrylcarnitine (2)	0.20	0.0289
	hexanoylcarnitine	0.12	0.0016
	myristoylcarnitine	0.38	0.0098
	palmitoylcarnitine	0.30	0.0182
	palmitoleylcarnitine	0.25	0.0003
	stearoylcarnitine	0.78	0.2586
	linoleoylcarnitine	0.64	0.0292
	oleoylcarnitine	0.18	0.0207
	myristoleoylcarnitine	1.36	0.3272
Carnitine Metabolism	deoxycarnitine	0.53	0.0015
	carnitine	0.63	0.0197
Fatty Acid, Monohydroxy	4-hydroxybutyrate (GHB)	4.86	0.0964
	2-hydroxypalmitate	1.54	0.1974
	2-hydroxystearate	1.66	0.1807
	3-hydroxyhexanoate	1.67	0.0036
	3-hydroxyoctanoate	1.52	0.0253
	3-hydroxydecanoate	1.63	0.0076
	3-hydroxylaurate	1.10	0.6897
	3-hydroxypalmitate	0.89	0.2564
	13-HODE + 9-HODE	1.05	0.4504
	3-hydroxystearate	0.59	0.3031
Inositol Metabolism	myo-inositol	0.55	0.0003
	inositol 1-phosphate (I1P)	0.66	0.0887
Phospholipid Metabolism	choline	1.03	0.7164
	choline phosphate	0.79	0.1359
	cytidine 5'-diphosphocholine	1.20	0.7929
	glycerophosphorylcholine (GPC)	5.75	0.1725
	phosphoethanolamine	0.33	0.0054
	cytidine-5'-diphosphoethanolamine	0.45	0.0326
	glycerophosphoethanolamine	0.90	0.7911
	trimethylamine N-oxide	0.93	0.4093
	glycerophosphoinositol	0.71	0.6835
	1,2-dipalmitoyl-GPC (16:0/16:0)	0.59	0.0653
	1-palmitoyl-2-oleoyl-GPC (16:0/18:1)	1.09	0.1505
	1-palmitoyl-2-linoleoyl-GPC (16:0/18:2)	0.75	0.0309
	1-stearoyl-2-oleoyl-GPC (18:0/20:4)	2.29	0.0942
	1-stearoyl-2-oleoyl-GPC (18:0/18:1)	2.72	0.0566
	1-stearoyl-2-oleoyl-GPI (18:0/18:1)	2.06	0.0733
	1,2-dioleoyl-GPC (18:1/18:1)	2.48	0.0535
	1-palmitoyl-2-arachidonoyl-GPC (16:0/20:4)	0.82	0.2087
	1-stearoyl-2-linoleoyl-GPC (18:0/18:2)	1.85	0.0992
	1-palmitoleoyl-2-oleoyl-GPC (16:1/18:1)	1.28	0.2020
	1-palmitoyl-2-palmitoleoyl-GPC (16:0/16:1)	0.60	0.0306

Phospholipid Metabolism	1-stearoyl-2-arachidonoyl-GPI (18:0/20:4)	0.69	0.0363
	1-oleoyl-2-linoleoyl-GPC (18:1/18:2)	1.20	0.0802
	1-palmitoyl-2-arachidonoyl-GPI (16:0/20:4)	0.51	0.0414
	1-palmitoyl-2-oleoyl-GPG (16:0/18:1)	0.76	0.2119
	1-palmitoyl-2-oleoyl-GPE (16:0/18:1)	0.72	0.0496
	1-stearoyl-2-arachidonoyl-GPE (18:0/20:4)	0.83	0.1658
	1-stearoyl-2-oleoyl-GPE (18:0/18:1)	2.65	0.0402
	1-palmitoyl-2-arachidonoyl-GPE (16:0/20:4)	0.44	0.0306
	1-palmitoyl-2-linoleoyl-GPE (16:0/18:2)	0.43	0.0273
	1-stearoyl-2-linoleoyl-GPE (18:0/18:2)	0.79	0.0857
	1-palmitoyl-2-stearoyl-GPC (16:0/18:0)	0.60	0.0356
	1,2-dioleoyl-GPE (18:1/18:1)	1.67	0.0026
	1-palmitoyl-2-oleoyl-GPI (16:0/18:1)	3.13	0.0170
	1,2-dioleoyl-GPS (18:1/18:1)	2.00	0.0503
	1-palmitoyl-2-alpha-linolenoyl-GPC (16:0/18:3n3)	0.77	0.1573
	1-palmitoleoyl-2-linoleoyl-GPC (16:1/18:2)	0.59	0.0043
	1-palmitoleoyl-2-linolenoyl-GPC (16:1/18:3)	0.40	0.0415
	1,2-dilinoleoyl-GPC (18:2/18:2)	1.06	0.5679
	1-oleoyl-2-linoleoyl-GPE (18:1/18:2)	0.67	0.0552
	1,2-distearoyl-GPC (18:0/18:0)	0.42	0.0341
	1-palmitoyl-2-oleoyl-GPS (16:0/18:1)	0.68	0.0579
	1-stearoyl-2-linoleoyl-GPS (18:0/18:2)	1.29	0.1616
Phosphatidylserine (PS)	oleoylcholine	1.32	0.8961
	palmitoloylcholine	0.89	0.7288
Phosphatidylserine (PS)	1-palmitoyl-2-gamma-linolenoyl-GPC (16:0/18:3n6)	0.56	0.0026
	1-stearoyl-2-arachidonoyl-GPS (18:0/20:4)	0.70	0.1537
Lysolipid	1-stearoyl-2-oleoyl-GPS (18:0/18:1)	3.81	0.0551
	1-palmitoyl-GPC (16:0)	0.60	0.0275
	2-palmitoyl-GPC (16:0)	0.84	0.2420
	1-palmitoleoyl-GPC (16:1)	0.48	0.0038
	2-palmitoleoyl-GPC (16:1)	1.19	0.2436
	1-stearoyl-GPC (18:0)	1.10	0.7946
	1-oleoyl-GPC (18:1)	1.05	0.6838
	1-linoleoyl-GPC (18:2)	0.90	0.4276
	1-arachidonoyl-GPC (20:4n6)	1.60	0.0902
	1-lignoceroyl-GPC (24:0)	8.62	0.0804
	1-palmitoyl-GPE (16:0)	0.30	0.0224
	1-stearoyl-GPE (18:0)	0.52	0.0035
	2-stearoyl-GPE (18:0)	0.47	0.0080
	1-oleoyl-GPE (18:1)	0.74	0.0945
	1-linoleoyl-GPE (18:2)	0.84	0.3231
	1-arachidonoyl-GPE (20:4n6)	0.98	0.8755
	1-palmitoyl-GPI (16:0)	1.13	0.6493
	1-stearoyl-GPI (18:0)	1.41	0.1793
	1-oleoyl-GPI (18:1)	2.58	0.0112
	1-arachidonoyl-GPI (20:4)	1.48	0.0909
	1-stearoyl-GPS (18:0)	0.58	0.0135

	1-oleoyl-GPS (18:1)	2.07	0.0824
	1-palmitoyl-GPG (16:0)	0.89	0.5518
	1-palmitoyl-GPS (16:0)	0.34	0.0342
	1-stearoyl-GPG (18:0)	1.00	---
	1-oleoyl-GPG (18:1)	1.13	0.6704
	1-linoleoyl-GPG (18:2)	1.10	0.8341
Plasmalogen	1-(1-enyl-palmitoyl)-2-oleoyl-GPE (P-16:0/18:1)	12.66	0.0552
	1-(1-enyl-palmitoyl)-2-linoleoyl-GPE (P-16:0/18:2)	26.21	0.0890
	1-(1-enyl-palmitoyl)-2-palmitoyl-GPC (P-16:0/16:0)	0.75	0.0187
	1-(1-enyl-palmitoyl)-2-palmitoleoyl-GPC (P-16:0/16:1)	1.43	0.7890
	1-(1-enyl-palmitoyl)-2-arachidonoyl-GPE (P-16:0/20:4)	0.85	0.3651
	1-(1-enyl-palmitoyl)-2-oleoyl-GPC (P-16:0/18:1)	1.95	0.2768
	1-(1-enyl-stearoyl)-2-oleoyl-GPE (P-18:0/18:1)	22.43	0.0208
	1-(1-enyl-stearoyl)-2-linoleoyl-GPE (P-18:0/18:2)	53.55	0.0153
	1-(1-enyl-palmitoyl)-2-arachidonoyl-GPC (P-16:0/20:4)	1.00	---
	1-(1-enyl-stearoyl)-2-arachidonoyl-GPE (P-18:0/20:4)	0.87	0.2479
Lysoplasmalogen	1-(1-enyl-palmitoyl)-GPC (P-16:0)	1.38	0.1960
	1-(1-enyl-palmitoyl)-GPE (P-16:0)	7.43	0.0886
	1-(1-enyl-oleoyl)-GPE (P-18:1)	5.80	0.1412
	1-(1-enyl-stearoyl)-GPE (P-18:0)	5.03	0.1057
	1-(1-enyl-oleoyl)-2-oleoyl-GPE (P-18:1/18:1)	59.98	0.0123
Glycerolipid Metabolism	glycerol	4.35	0.0006
	glycerol 3-phosphate	0.63	0.2377
	glycerophosphoglycerol	1.36	0.5881
Monoacylglycerol	1-myristoylglycerol (14:0)	1.14	0.6593
	2-myristoylglycerol (14:0)	1.34	0.8906
	1-myristoleoylglycerol (14:1)	0.66	0.1597
	1-pentadecanoylglycerol (15:0)	1.00	0.6381
	1-palmitoylglycerol (16:0)	1.04	0.5856
	2-palmitoylglycerol (16:0)	1.27	0.9940
	1-margaroylglycerol (17:0)	1.42	0.4550
	1-oleoylglycerol (18:1)	1.23	0.9220
	2-oleoylglycerol (18:1)	1.32	0.7477
	1-linoleoylglycerol (18:2)	0.77	0.2275
	2-linoleoylglycerol (18:2)	0.81	0.2623
	1-linolenoylglycerol (18:3)	0.68	0.1573
	1-arachidonoylglycerol (20:4)	0.78	0.2361
	2-arachidonoylglycerol (20:4)	0.82	0.3202
	1-docosahexaenoylglycerol (22:6)	0.66	0.1383
	1-dihomo-linolenylglycerol (20:3)	0.78	0.2203
	2-docosahexaenoylglycerol (22:6)	0.72	0.1949
	1-palmitoleoylglycerol (16:1)	0.75	0.1916
	2-palmitoleoylglycerol (16:1)	0.79	0.2169
	1-eicosapentaenoylglycerol (20:5)	0.62	0.1297
	2-eicosapentaenoylglycerol (20:5)	0.65	0.1938

Diacylglycerol	palmitoleyl-oleoyl-glycerol (16:1/18:1) [1]	0.44	0.0492
	oleoyl-linoleoyl-glycerol (18:1/18:2) [2]	1.08	0.5366
	palmitoleyl-oleoyl-glycerol (16:1/18:1) [2]	0.75	0.2098
	palmitoyl-linoleoyl-glycerol (16:0/18:2) [1]	0.34	0.0310
	palmitoyl-linoleoyl-glycerol (16:0/18:2) [2]	0.76	0.2265
Sphingolipid Metabolism	N-palmitoyl-sphinganine (d18:0/16:0)	1.65	0.1425
	sphinganine	2.01	0.0003
	phytosphingosine	1.31	0.8474
	palmitoyl sphingomyelin (d18:1/16:0)	1.46	0.1420
	stearoyl sphingomyelin (d18:1/18:0)	1.47	0.3705
	sphingomyelin (d18:1/18:1, d18:2/18:0)	1.43	0.2397
	sphingosine	1.90	0.0012
	N-palmitoyl-sphingosine (d18:1/16:0)	2.50	0.0495
	sphingomyelin (d18:1/14:0, d16:1/16:0)	1.06	0.2318
	sphingomyelin (d18:2/14:0, d18:1/14:1)	1.54	0.0557
	sphingomyelin (d18:1/24:1, d18:2/24:0)	1.36	0.7458
	sphingomyelin (d18:2/16:0, d18:1/16:1)	1.19	0.4829
	sphingomyelin (d18:1/20:1, d18:2/20:0)	0.78	0.1103
	behenoyl sphingomyelin (d18:1/22:0)	0.89	0.4427
	sphingomyelin (d18:1/22:1, d18:2/22:0, d16:1/24:1)	0.99	0.7914
	sphingomyelin (d18:1/20:0, d16:1/22:0)	0.74	0.0405
	palmitoyl dihydrosphingomyelin (d18:0/16:0)	0.70	0.0452
	sphingomyelin (d18:1/15:0, d16:1/17:0)	1.01	0.8567
	sphingomyelin (d18:1/21:0, d17:1/22:0, d16:1/23:0)	1.09	0.6043
	sphingomyelin (d18:2/23:0, d18:1/23:1, d17:1/24:1)	1.46	0.3541
	sphingomyelin (d18:2/24:1, d18:1/24:2)	1.59	0.5426
Mevalonate Metabolism	tricosanoyl sphingomyelin (d18:1/23:0)	1.02	0.9753
	sphingomyelin (d18:1/17:0, d17:1/18:0, d19:1/16:0)	3.88	0.0901
	glycosyl-N-stearoyl-sphingosine	11.31	0.0459
Glycolysis, Gluconeogenesis, and Pyruvate Metabolism	glycosyl-N-palmitoyl-sphingosine	4.08	0.0159
	lactosyl-N-palmitoyl-sphingosine	4.27	0.0088
	3-hydroxy-3-methylglutarate	0.38	0.0007
	glucose	0.94	0.5541
	glucose 6-phosphate	4.49	0.0673
	fructose-6-phosphate	2.22	0.0323
	Isobar: fructose 1,6-diphosphate, glucose 1,6-diphosphate, myo-inositol 1,4 or 1,3-diphosphate	0.56	0.1159
	dihydroxyacetone phosphate (DHAP)	0.77	0.2202
	3-phosphoglycerate	0.99	0.6846
	phosphoenolpyruvate (PEP)	0.62	0.0736
	pyruvate	1.12	0.6783
	lactate	0.81	0.0830
	glycerate	2.02	0.1113
	citrate	0.50	0.0629
	aconitate [cis or trans]	1.00	0.7524

TCA Cycle	isocitrate	1.16	0.3739
	alpha-ketoglutarate	0.68	0.1351
	succinylcarnitine	1.09	0.7225
	succinate	0.46	0.0668
	fumarate	0.88	0.3338
	malate	0.89	0.4420
	itaconate	40.08	0.0329
	2-methylcitrate/homocitrate	1.10	0.3451
Oxidative Phosphorylation	acetylphosphate	0.70	0.1904
	phosphate	1.19	0.1575
Glutamate Metabolism	glutamate	0.74	0.0234
	glutamine	0.97	0.6107
	N-acetylglutamate	0.24	0.0157
	N-acetylglutamine	0.43	0.0411
	N-acetyl-aspartyl-glutamate (NAAG)	0.36	0.0391
	gamma-aminobutyrate (GABA)	1.58	0.3181
	4-hydroxyglutamate	8.55	0.0002
	glutamate, gamma-methyl ester	2.21	0.1721
	pyroglutamine*	0.82	0.2281
	gamma-carboxyglutamate	1.49	0.1142
	S-1-pyrroline-5-carboxylate	1.82	0.2485

List of detected metabolites. Statistical comparison of fold-changes between groups (T β T-Hep3B/Hep3B) was performed by Welch's two-sample t-test. p<0.05 was considered significant. Values <1 indicate lower levels (green shading colour when significant) and values >1 indicate higher levels (red shading colour when significant) as compared to Hep3B.

Table S2.List of analyzed genes in T β T-Hep3B and compared to Hep3B

Sub pathway	Symbol	GenBank	Description	T β T-Hep3B Hep3B	p-value
Acetyl-CoA transferases	<i>ACAA1</i>	NM_001607	Acetyl-CoA acyltransferase 1	1.49	0.0554
	<i>ACAA2</i>	NM_006111	Acetyl-CoA acyltransferase 2	0.86	0.2428
	<i>ACAT1</i>	NM_000019	Acetyl-CoA acetyltransferase 1	0.98	0.8353
	<i>ACAT2</i>	NM_005891	Acetyl-CoA acetyltransferase 2	1.91	0.0015
Acyl-CoA dehydrogenases	<i>ACAD9</i>	NM_014049	Acyl-CoA dehydrogenase family, member 9	1.18	0.1576
	<i>ACAD10</i>	NM_025247	Acyl-CoA dehydrogenase family, member 10	1.36	0.1942
	<i>ACAD11</i>	NM_032169	Acyl-CoA dehydrogenase family, member 11	1.59	0.0127
	<i>ACADL</i>	NM_001608	Acyl-CoA dehydrogenase, long chain	0.01	0.0883
	<i>ACADM</i>	NM_000016	Acyl-CoA dehydrogenase, C-4 to C-12 straight chain	1.31	0.4198
	<i>ACADS</i>	NM_000017	Acyl-CoA dehydrogenase, C-2 to C-3 short chain	1.23	0.3524
	<i>ACADSB</i>	NM_001609	Acyl-CoA dehydrogenase, short/branched chain	1.03	0.7327
	<i>ACADVL</i>	NM_000018	Acyl-CoA dehydrogenase, very long chain	1.80	0.0110
	<i>EHHADH</i>	NM_001966	Enoyl-CoA, hydratase/3-hydroxyacyl CoA dehydrogenase	1.69	0.0444
	<i>GCDH</i>	NM_000159	Glutaryl-CoA dehydrogenase	1.06	0.7648
Acyl-CoA oxidases	<i>ACOX1</i>	NM_004035	Acyl-CoA oxidase 1, palmitoyl	0.85	0.1596
	<i>ACOX2</i>	NM_003500	Acyl-CoA oxidase 2, branched chain	0.79	0.5230
	<i>ACOX3</i>	NM_003501	Acyl-CoA oxidase 3, pristanoyl	1.16	0.3687
Acyl-CoA synthetases	<i>ACACA</i>	NM_198834	Acetyl-CoA Carboxylase Alpha	1.32	0.7337
	<i>ACACB</i>	NM_001093	Acetyl-CoA Carboxylase Beta	2.31	0.3639
	<i>ACLY</i>	NM_001096	ATP citrate lyase	1.36	0.0456
	<i>ACSBG1</i>	NM_015162	Acyl-CoA synthetase bubblegum family member 1	N/A	N/A
	<i>ACSBG2</i>	NM_030924	Acyl-CoA synthetase bubblegum family member 2	N/A	N/A
	<i>ACSL1</i>	NM_001995	Acyl-CoA synthetase long-chain family member 1	0.38	0.0025
	<i>ACSL3</i>	NM_004457	Acyl-CoA synthetase long-chain family member 3	2.42	0.0003
	<i>ACSL4</i>	NM_004458	Acyl-CoA synthetase long-chain family member 4	1.26	0.1378
	<i>ACSL5</i>	NM_016234	Acyl-CoA synthetase long-chain family member 5	5.60	0.0008
	<i>ACSL6</i>	NM_001009185	Acyl-CoA synthetase long-chain family member 6	2.23	0.0168
	<i>ACSM3</i>	NM_005622	Acyl-CoA synthetase medium-chain family member 3	3.05	0.1646
	<i>ACSM4</i>	NM_001080454	Acyl-CoA synthetase medium-chain family member 4	N/A	N/A
	<i>ACSM5</i>	NM_017888	Acyl-CoA synthetase medium-chain family member 5	N/A	N/A
Acyl-CoA thioesterases	<i>ACOT1</i>	NM_001037161	Acyl-CoA thioesterase 1	1.37	0.1767
	<i>ACOT6</i>	NM_001037162	Acyl-CoA thioesterase 6	N/A	N/A
	<i>ACOT7</i>	NM_181866	Acyl-CoA thioesterase 7	0.94	0.6966
	<i>ACOT8</i>	NM_005469	Acyl-CoA thioesterase 8	1.67	0.0109
	<i>ACOT9</i>	NM_001033583	Acyl-CoA thioesterase 9	0.97	0.7930
	<i>ACOT12</i>	NM_130767	Acyl-CoA thioesterase 12	N/A	N/A
	<i>CPT1A</i>	NM_001876	Carnitine palmitoyltransferase 1A (liver)	0.82	0.1909
	<i>CPT1B</i>	NM_004377	Carnitine palmitoyltransferase 1B (muscle)	N/A	N/A
	<i>CPT1C</i>	NM_152359	Carnitine palmitoyltransferase 1C	N/A	N/A

Fatty acid transport	<i>CPT2</i>	NM_000098	Carnitine palmitoyltransferase 2	1.06	0.8746
	<i>CRAT</i>	NM_000755	Carnitine O-acetyltransferase	2.39	0.0025
	<i>CROT</i>	NM_021151	Carnitine O-octanoyltransferase	1.16	0.1913
	<i>FABP1</i>	NM_001443	Fatty acid binding protein 1, liver	4.68	0.0002
	<i>FABP2</i>	NM_000134	Fatty acid binding protein 2, intestinal	N/A	N/A
	<i>FABP3</i>	NM_004102	Fatty acid binding protein 3, muscle and heart (mammary-derived growth)	2.01	0.0092
	<i>FABP4</i>	NM_001442	Fatty acid binding protein 4, adipocyte	N/A	N/A
	<i>FABP5</i>	NM_001444	Fatty acid binding protein 5 (psoriasis-associated)	1.29	0.2563
	<i>FABP6</i>	NM_001445	Fatty acid binding protein 6, ileal	1.41	0.1823
	<i>FABP7</i>	NM_001446	Fatty acid binding protein 7, brain	N/A	N/A
	<i>SLC27A1</i>	NM_198580	Solute carrier family 27 (fatty acid transporter), member 1	3.82	0.0289
	<i>SLC27A2</i>	NM_003645	Solute carrier family 27 (fatty acid transporter), member 2	0.99	0.9481
	<i>SLC27A3</i>	NM_024330	Solute carrier family 27 (fatty acid transporter), member 3	1.63	0.1217
	<i>SLC27A4</i>	NM_005094	Solute carrier family 27 (fatty acid transporter), member 4	1.43	0.0163
	<i>SLC27A5</i>	NM_012254	Solute carrier family 27 (fatty acid transporter), member 5	1.76	0.0058
	<i>SLC27A6</i>	NM_014031	Solute carrier family 27 (fatty acid transporter), member 6	N/A	N/A
Biosynthesis regulation	<i>FASN</i>	NM_004104	Fatty acid synthase	1.14	0.5467
	<i>PPAR α</i>	NM_001001928	Peroxisome proliferator-activated receptor alpha	1.67	0.3758
	<i>PPAR γ</i>	NM_138712.3	Peroxisome proliferator-activated receptor gamma	2.65	0.0815
	<i>PPAR δ</i>	NM_006238.4	Peroxisome proliferator-activated receptor delta	1.40	0.4283
	<i>PRKAA1</i>	NM_006251	Protein kinase, AMP-activated, alpha 1 catalytic subunit	1.21	0.0501
	<i>PRKAA2</i>	NM_006252	Protein kinase, AMP-activated, alpha 2 catalytic subunit	0.76	0.0277
	<i>PRKAB1</i>	NM_006253	Protein kinase, AMP-activated, beta 1 non-catalytic subunit	1.47	0.0379
	<i>PRKAB2</i>	NM_005399	Protein kinase, AMP-activated, beta 2 non-catalytic subunit	0.81	0.0186
	<i>PRKACA</i>	NM_002730	Protein kinase, cAMP-dependent, catalytic, alpha	1.12	0.5596
	<i>PRKACB</i>	NM_182948	Protein kinase, cAMP-dependent, catalytic, beta	1.01	0.8986
	<i>PRKAG1</i>	NM_002733	Protein kinase, AMP-activated, gamma 1 non-catalytic subunit	1.33	0.0048
	<i>PRKAG2</i>	NM_016203	Protein kinase, AMP-activated, gamma 2 non-catalytic subunit	2.36	0.0004
	<i>PRKAG3</i>	NM_017431	Protein kinase, AMP-activated, gamma 3 non-catalytic subunit	N/A	N/A
Ketogenesis	<i>BDH1</i>	NM_004051	3-hydroxybutyrate dehydrogenase, type 1	1.01	0.8478
	<i>BDH2</i>	NM_020139	3-hydroxybutyrate dehydrogenase, type 2	0.95	0.6457
	<i>HMGCL</i>	NM_000191	3-hydroxymethyl-3-methylglutaryl-CoA lyase	1.65	0.0080
	<i>HMGCS1</i>	NM_002130	3-hydroxy-3-methylglutaryl-CoA synthase 1 (soluble)	2.13	0.0148
	<i>HMGCS2</i>	NM_005518	3-hydroxy-3-methylglutaryl-CoA synthase 2 (mitochondrial)	N/A	N/A
	<i>OXCT2</i>	NM_022120	3-oxoacid CoA transferase 2	0.68	0.0800
Triacylglycerol	<i>GK</i>	NM_000167	Glycerol kinase	0.85	0.6554
	<i>GK2</i>	NM_033214	Glycerol kinase 2	N/A	N/A
	<i>GPD1</i>	NM_005276	Glycerol-3-phosphate dehydrogenase 1 (soluble)	1.65	0.0418

metabolism	<i>GPD2</i>	NM_000408	Glycerol-3-phosphate dehydrogenase 2 (mitochondrial)	1.17	0.1327
	<i>LIPE</i>	NM_005357	Lipase, hormone-sensitive	2.61	0.0719
	<i>LPL</i>	NM_000237	Lipoprotein lipase	N/A	N/A
Others	<i>ALDH2</i>	NM_000690	Aldehyde dehydrogenase 2 family (mitochondrial)	1.29	0.3847
	<i>DECRI</i>	NM_001359	2,4-dienoyl CoA reductase 1, mitochondrial	0.71	0.0231
	<i>DECR2</i>	NM_020664	2,4-dienoyl CoA reductase 2, peroxisomal	1.03	0.9130
	<i>ECHS1</i>	NM_004092	Enoyl CoA hydratase, short chain, 1, mitochondrial	1.14	0.2265
	<i>ECI2</i>	NM_006117	Enoyl-CoA delta isomerase 2	0.82	0.0781
	<i>HADHA</i>	NM_000182	Hydroxyacyl-CoA dehydrogenase/3-ketoacyl-CoA thiolase/enoyl-CoA hydratase	1.31	0.0945
	<i>MCEE</i>	NM_032601	Methylmalonyl CoA epimerase	1.60	0.0005
	<i>MUT</i>	NM_000255	Methylmalonyl CoA mutase	1.37	0.0949
	<i>PECR</i>	NM_018441	Peroxisomal trans-2-enoyl-CoA reductase	1.61	0.0150
	<i>PPA1</i>	NM_021129	Pyrophosphatase (inorganic) 1	1.04	0.6164

Sub Pathway	Symbol	GenBank	Description	<u>T_BT-Hep3B</u> Hep3B	p-value
Glycolysis	<i>ALDOA</i>	NM_000034	Aldolase A, fructose-bisphosphate	1.54	0.3746
	<i>ALDOB</i>	NM_000035	Aldolase B, fructose-bisphosphate	N/A	N/A
	<i>ALDOC</i>	NM_005165	Aldolase C, fructose-bisphosphate	1.49	0.0262
	<i>BPGM</i>	NM_001724	2,3-bisphosphoglycerate mutase	1.59	0.0643
	<i>ENO1</i>	NM_001428	Enolase 1, (alpha)	0.93	0.7141
	<i>ENO2</i>	NM_001975	Enolase 2 (gamma, neuronal)	0.50	0.1153
	<i>ENO3</i>	NM_001976	Enolase 3 (beta, muscle)	0.69	0.2976
	<i>GALM</i>	NM_138801	Galactose mutarotase (aldose 1-epimerase)	0.84	0.4465
	<i>GCK</i>	NM_000162	Glucokinase (hexokinase 4)	N/A	N/A
	<i>GPI</i>	NM_000175	Glucose-6-phosphate isomerase	1.55	0.3617
	<i>HK2</i>	NM_000189	Hexokinase 2	1.81	0.6340
	<i>HK3</i>	NM_002115	Hexokinase 3 (white cell)	N/A	N/A
	<i>LDHA</i>	NM_005566	Lactate dehydrogenase A	1.22	0.2212
	<i>LDHB</i>	NM_002300	Lactate dehydrogenase B	N/A	N/A
	<i>PFKL</i>	NM_002626	Phosphofructokinase, liver	1.06	0.8032
	<i>PGAM2</i>	NM_000290	Phosphoglycerate mutase 2 (muscle)	0.28	0.0007
	<i>PGK1</i>	NM_000291	Phosphoglycerate kinase 1	0.76	0.3228
	<i>PGK2</i>	NM_138733	Phosphoglycerate kinase 2	0.85	0.6522
	<i>PGM1</i>	NM_002633	Phosphoglucomutase 1	2.04	0.1234
	<i>PGM2</i>	NM_018290	Phosphoglucomutase 2	0.95	0.7028
	<i>PGM3</i>	NM_015599	Phosphoglucomutase 3	0.93	0.7493
	<i>PKLR</i>	NM_000298	Pyruvate kinase, liver and RBC	7.07	0.0604
	<i>PKM2</i>	NM_002654	Pyruvate kinase, muscle 2	0.78	0.4184
	<i>TPI1</i>	NM_000365	Triosephosphate isomerase 1	0.75	0.4871
	<i>SLC2A1</i>	NM_006516	Solute carrier family 2 (facilitated glucose transporter), member 1	1.14	0.1090
	<i>SLC2A2</i>	NM_000340	Solute carrier family 2 (facilitated glucose transporter), member 2	0.67	0.0541
	<i>SLC2A3</i>	NM_006931	Solute carrier family 2 (facilitated glucose transporter), member 3	0.77	0.2152
	<i>SLC2A4</i>	NM_001042	Solute carrier family 2 (facilitated glucose transporter), member 4	2.18	0.1921
<i>PDK1</i>	<i>PDK1</i>	NM_002610	Pyruvate dehydrogenase kinase, isozyme 1	0.68	0.2717
	<i>PDK2</i>	NM_002611	Pyruvate dehydrogenase kinase, isozyme 2	1.64	0.1585

Pyruvate dehydrogenase regulation	<i>PDK3</i>	NM_005391	Pyruvate dehydrogenase kinase, isozyme 3	1.02	0.9694
	<i>PDK4</i>	NM_002612	Pyruvate dehydrogenase kinase, isozyme 4	3.57	0.0436
	<i>PDP2</i>	NM_020786	Pyruvate dehydrogenase phosphatase catalytic subunit 2	1.34	0.5304
	<i>PDPR</i>	NM_017990	Pyruvate dehydrogenase phosphatase regulatory subunit	1.09	0.6094
Pyruvate dehydrogenase complex	<i>DLAT</i>	NM_001931	Dihydrolipoamide S-acetyltransferase	0.94	0.8611
	<i>DLD</i>	NM_000108	Dihydrolipoamide dehydrogenase	1.52	0.1825
	<i>DLST</i>	NM_001933	Dihydrolipoamide S-succinyltransferase	1.43	0.1666
	<i>PDHA1</i>	NM_000284	Pyruvate dehydrogenase (lipoamide) alpha 1	1.21	0.1399
	<i>PDHB</i>	NM_000925	Pyruvate dehydrogenase (lipoamide) beta	1.33	0.0121
TCA cycle	<i>ACLY</i>	NM_001096	ATP citrate lyase	1.36	0.0456
	<i>ACO1</i>	NM_002197	Aconitase 1, soluble	1.61	0.0019
	<i>ACO2</i>	NM_001098	Aconitase 2, mitochondrial	2.16	0.2250
	<i>CS</i>	NM_004077	Citrate synthase	1.14	0.6518
	<i>FH</i>	NM_000143	Fumarate hydratase	0.98	0.8067
	<i>IDH1</i>	NM_005896	Isocitrate dehydrogenase 1 (NADP+), soluble	1.28	0.1670
	<i>IDH2</i>	NM_002168	Isocitrate dehydrogenase 2 (NADP+), mitochondrial	1.00	0.9803
	<i>IDH3A</i>	NM_005530	Isocitrate dehydrogenase 3 (NAD+) alpha	1.44	0.1534
	<i>IDH3B</i>	NM_174856	Isocitrate dehydrogenase 3 (NAD+) beta	1.36	0.1599
	<i>IDH3G</i>	NM_174869	Isocitrate dehydrogenase 3 (NAD+) gamma	1.16	0.2548
	<i>MDH1</i>	NM_005917	Malate dehydrogenase 1, NAD (soluble)	1.05	0.4306
	<i>MDH1B</i>	NM_001039845	Malate dehydrogenase 1B, NAD (soluble)	1.66	0.3292
	<i>MDH2</i>	NM_005918	Malate dehydrogenase 2, NAD (mitochondrial)	1.36	0.3681
	<i>OGDH</i>	NM_002541	Oxoglutarate dehydrogenase	1.54	0.1297
	<i>PC</i>	NM_000920	Pyruvate carboxylase	1.17	0.2044
	<i>PCK1</i>	NM_002591	Phosphoenolpyruvate carboxykinase 1 (soluble)	1.47	0.4258
	<i>PCK2</i>	NM_004563	Phosphoenolpyruvate carboxykinase 2	0.99	0.9723
	<i>SDHA</i>	NM_004168	Succinate dehydrogenase complex, subunit A, flavoprotein (Fp)	1.21	0.4673
	<i>SDHB</i>	NM_003000	Succinate dehydrogenase complex, subunit B, iron sulfur (Ip)	1.17	0.2019
	<i>SDHC</i>	NM_003001	Succinate dehydrogenase complex, subunit C, integral membrane protein	1.92	0.0836
	<i>SDHD</i>	NM_003001	Succinate dehydrogenase complex, subunit D, integral membrane protein	1.21	0.4810
	<i>SUCLA2</i>	NM_003850	Succinate-CoA ligase, ADP-forming, beta subunit	1.22	0.3138
	<i>SUCLG1</i>	NM_003849	Succinate-CoA ligase, alpha subunit	0.84	0.5854
	<i>SUCLG2</i>	NM_003848	Succinate-CoA ligase, GDP-forming, beta subunit	1.23	0.5511
Glutamine Metabolism	<i>GLS1</i>	NM_014905	Glutaminase 1	1.21	0.0995
	<i>GLS2</i>	NM_013267	Glutaminase 2	N/A	N/A
	<i>SLC1A5</i>	NM_005628	Solute carrier family 1 (neutral amino acid transporter), member 5	0.97	0.9588
	<i>SLC7A5</i>	NM_003486	Solute carrier family 7 (amino acid transporter light chain, L system), member 5	0.64	0.0680

List of analyzed genes. Expression in fold comparing T β T-Hep3B to Hep3B. p<0.05 was considered significant. Values <1 indicate lower expression (green shading when significant) and values >1 indicate higher expression (red shading when significant) as compared to Hep3B. N/A indicates Ct values >35 and was considered as non-detectable expression.